![]() ![]() |
|||||||||||
![]()
![]() ![]()
|
![]() You’ve been prescribed ENDOMETRIN®, the new vaginal progesterone insert approved by the FDA for use in ART treatment. Progesterone is a natural hormone often prescribed following ovulation and egg retrieval (called the "luteal phase") to help prepare the uterine lining (endometrium) to receive and nourish a fertilized egg. Importantly, ENDOMETRIN® was shown to help achieve excellent pregnancy rates in the largest IVF trial ever conducted in the United States with 1211 patients.1 Each ENDOMETRIN® insert supplies 100 mg of natural progesterone and comes with its own specially designed, disposable applicator for clean, comfortable insertion into the vagina, 2 or 3 times a day as prescribed by your doctor.2 Your doctor will have you begin using ENDOMETRIN® starting at egg retrieval, and upon a positive pregnancy test, continue for up to 10 weeks total duration. And here’s what women who used ENDOMETRIN in the clinical trial had to say: Nearly 80% would recommend ENDOMETRIN® to a friend, and 70% who had used other forms of progesterone believe ENDOMETRIN® is better or much better.3 That’s important to know, because other forms of progesterone which have been prescribed for luteal support are often difficult for many women to use.
What’s more, ENDOMETRIN® is FDA approved; and, of all these forms of progesterone, none has been as extensively studied as ENDOMETRIN® in a clinical trial with over 1200 patients. Another advantage: ENDOMETRIN can be inserted while you are standing, sitting, or when lying on your back with your knees bent. Other progesterone products require you to lie down when inserting them and to remain lying down for a period of time afterwards. We invite you to ask your doctor about ENDOMETRIN® as well as any other questions you may have about your treatment. Please note: ENDOMETRIN® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women. References: 1. Doody K, Shamma FN, Paulson RJ, et al. Endometrin® for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur® and Bravelle®. Presented at: 55th Annual Meeting of the Pacific Coast Reproductive Society; April 18-22, 2007; Rancho Mirage, California. 2. Endometrin® [prescribing information]. Suffern, NY: Ferring Pharmaceuticals Inc; June 2007. 3. Data on File. Ferring Pharmaceuticals Inc. Patient Prescribing Information
|
|||||||